Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,079 shares of the specialty pharmaceutical company’s stock after selling 3,604 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.10% of Jazz Pharmaceuticals worth $7,522,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of JAZZ. Barclays PLC boosted its holdings in Jazz Pharmaceuticals by 19.1% in the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock valued at $4,369,000 after purchasing an additional 6,289 shares during the last quarter. Park Avenue Securities LLC raised its position in Jazz Pharmaceuticals by 19.5% in the fourth quarter. Park Avenue Securities LLC now owns 2,521 shares of the specialty pharmaceutical company’s stock valued at $310,000 after purchasing an additional 412 shares during the period. Arkadios Wealth Advisors purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $716,000. Kera Capital Partners Inc. purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $288,000. Finally, Aaron Wealth Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $301,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This trade represents a 36.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Seamus Mulligan purchased 1,621 shares of the firm’s stock in a transaction on Monday, May 12th. The stock was bought at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the acquisition, the director now owns 101,621 shares in the company, valued at $10,466,963. The trade was a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Trading Up 2.7%

Shares of Jazz Pharmaceuticals stock opened at $108.98 on Friday. The company has a 50-day moving average of $115.73 and a two-hundred day moving average of $122.01. The stock has a market cap of $6.72 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.68 earnings per share. On average, research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Barclays reaffirmed an “overweight” rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, StockNews.com cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.